Covid-19 Man­u­fac­tur­ing Roundup: Ther­mo Fish­er plant ramps up As­traZeneca vac­cine pro­duc­tion; No­vavax ex­pands Ko­re­an man­u­fac­tur­ing pact

Short­ly af­ter Ther­mo Fish­er’s $878.2 mil­lion buy­out of No­vasep’s vi­ral vec­tor man­u­fac­tur­ing busi­ness, it took over a plant in Bel­gium tasked with pro­duc­ing ade­n­ovirus vec­tors for As­traZeneca’s ver­sion of the Covid-19 shot.

That pro­duc­tion agree­ment was in­sti­gat­ed when No­vasep was still in charge, and the plant shoul­dered much of the blame for the oft-pub­li­cized slow­down of vac­cine out­put in re­cent weeks. Now that Ther­mo Fish­er has tak­en over, though, the plant has “dras­ti­cal­ly” ramped up its pro­duc­tion of late, Reuters re­port­ed Wednes­day. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.